Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 16/20 | 0.76 |
| ▸ | DPP9 | Q86TI2 | 14/20 | 0.76 |
| ▸ | DPP8 | Q6V1X1 | 14/20 | 0.76 |
| ▸ | DPP4 | P27487 | 7/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958752 | 0.85 | DPP9 (1.00) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL29940763 | 0.84 | DPP9 (1.00) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL14392574 | 0.84 | DPP9 (1.00) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL9032632 | 0.76 | DPP8 (0.82) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL9032640 | 0.76 | DPP8 (0.82) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL31463295 | 0.72 | ABHD6 (0.46) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL21747126 | 0.71 | DPP4 (0.74) | DPP7DPP9DPP8DPP4 | |
| SCHEMBL14067114 | 0.71 | NOTUM (0.62) | — | |
| SCHEMBL30142515 | 0.71 | ABHD6 (0.53) | DPP9DPP4 | |
| SCHEMBL12879433 | 0.71 | ABHD6 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200054655-A1 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | CASP1, CASP2, APAF1 | DPP7 910/4885DPP9 1286/4885DPP8 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.